MEVAXIDO - Multi-Epitope based Peptide Vaccine Design and Optimization

Welcome to MEVAXIDO, your resource for peptide vaccine design and optimization.

MEVAXIDO, or Multi-Epitope Based Peptide Vaccine Design and Optimization, is an advanced platform developed to streamline and enhance peptide vaccine design. Building on the limitations of traditional MEMP methodologies, MEVAXIDO incorporates an innovative approach to select B-cell epitopes that contain MHC I and II epitopes, aiming to stimulate both humoral and cellular immune responses. Our comprehensive screening process evaluates epitopes based on antigenicity, allergenicity, and toxicity, ensuring balanced consideration across these essential parameters. Furthermore, the application provides an optimized method that considers MEBP length, epitope number, sequence order, epitope repetition, linkers, and adjuvants to refine and elevate vaccine candidates.

One of MEVAXIDO's unique features is the integration of Percent Epitope Accessibility (PEA), a novel parameter that evaluates the 3D accessibility of epitopes, adding a new dimension to multi-epitope vaccine design. Through its user-friendly interface, MEVAXIDO not only supports users in understanding the new methodology but also offers additional tools and applications to simplify the design process, making it an indispensable resource in the field of vaccine development.

MEBPVC Optimizing Tools

Note: Click the button below to navigate to the PEA application.

Research Articles Associated with the MEBP Vaccine Improvised Methodology

• [1] Saha R, Ghosh P, Burra VLSP. Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches." 3 Biotech, 2021.
• [2] Salaikumaran MR, Kasamuthu PS, Aathmanathan VS, et al. An in silico approach to study the role of epitope order in the multi-epitope-based peptide (MEBP) vaccine design." Sci. Rep, 2022.
• [3] Sahoo PS, Burra VLSP. Evaluating the 3D structure prediction tools to identify optimal MEBPVC structure models." Computational and Structural Biotechnology Reports, 2024.

Funding and Support

This project is proudly supported by the Department of Science and Technology (DST) - National Supercomputing Mission (NSM) under the Government of India. The support and funding provided by DST-NSM have been essential in advancing the research and development activities within MEVAXIDO, enhancing its capabilities and impact in peptide vaccine design.

MEVAXIDO is funded under the following DST-NSM project grants:

• DST/NSM/R&D_HPC_Applications/2021/03.23
• DST/NSM/R&D_HPC_Applications/ Extension Grant/2023/30

These grants have provided critical resources for high-performance computing (HPC) applications, enabling the development of innovative methodologies, including multi-epitope screening and advanced optimization processes. DST-NSM’s commitment to fostering scientific innovation and computational research has been instrumental in MEVAXIDO’s success, allowing us to bring powerful, user-friendly tools to the scientific community in vaccine design and optimization.

Our Team

Dr. Burra V.L.S Prasad
Head and Professor, Center for Advanced Research and Innovation in Structural Biology of Diseases (CARISBD)
Department of Biotechnology, KLEF, Andhra Pradesh, India

Phone: 9810655546

Partha Sarathi Sahoo
Research Scholar, Center for Advanced Research and Innovation in Structural Biology of Diseases (CARISBD)
Department of Biotechnology, KLEF, Andhra Pradesh, India

Phone: 7654802349